The composition of biopharma boards is undergoing a profound transformation. For decades, the ideal board was built around scientific excellence, financial stewardship, governance expertise, and industry experience. While those capabilities remain essential, they are no longer sufficient on their own.
The pace of innovation, the convergence of biology and digital technology, evolving investor expectations, geopolitical uncertainty and increasingly complex capital markets are fundamentally changing what companies need from their directors.
I recently conducted a LinkedIn poll asking a simple but important question:
Which expertise will be most critical on biopharma boards by 2030?
The results were revealing:
- AI & Data – 46%
- Commercialisation – 23%
- Talent & Succession – 15%
- Capital Markets – 15%
Although the poll attracted a relatively small number of responses, the outcome mirrors many of the conversations I have with investors, CEOs, founders, board chairs and senior executives across the life sciences industry.
The question is no longer whether boards need to evolve.
The real question is how quickly they can evolve before the market moves ahead of them.
AI and Data Have Moved into the Boardroom
Artificial intelligence has rapidly progressed from being viewed as an operational tool to becoming a strategic capability that can fundamentally reshape business models.
Across biopharma, AI is influencing target identification, drug discovery, clinical trial design, manufacturing optimisation, regulatory submissions, supply chain management and commercial execution. The organisations that successfully harness these technologies will likely create significant competitive advantages over the coming decade.
For boards, this presents both opportunity and responsibility.
Directors do not necessarily need to become AI experts, but they must be capable of asking the right questions:
- Does management have an AI strategy aligned with business objectives?
- How robust is our data governance?
- What are the regulatory and cybersecurity implications?
- Where can AI accelerate value creation while maintaining appropriate oversight?
- How do we balance innovation with ethical considerations?
Digital literacy is increasingly becoming a core governance competency rather than a specialist skill.
Commercial Expertise is Becoming More Valuable Earlier
Commercialisation ranked second in the poll, reflecting another important shift within the industry.
Historically, commercial expertise often became a priority as products approached launch. Today, investors increasingly expect companies to consider commercial strategy much earlier in development.
Clinical development decisions directly influence reimbursement, pricing, patient access, market positioning and ultimately shareholder value.
Directors with deep commercial experience bring valuable perspectives on competitive positioning, global market access, launch planning and value creation that extend well beyond product approval.
Scientific excellence alone is rarely enough.
Successful companies must also excel at translating innovation into sustainable commercial success.
Talent May Be the Most Underrated Board Responsibility
While talent and succession planning received fewer votes, I would argue that it remains one of the most underestimated responsibilities of any board.
Every major strategic initiative ultimately depends upon leadership.
The competition for experienced scientific leaders, clinical development executives, digital specialists, regulatory experts and commercial talent has never been more intense.
Boards play a critical role in ensuring organisations have the leadership required not only for today’s challenges but also for those emerging five to ten years from now.
Succession planning should extend far beyond the CEO.
Building resilient executive teams capable of navigating constant change may prove to be one of the defining characteristics of successful biopharma companies during the next decade.
Capital Markets Expertise Remains Essential
Although capital markets ranked fourth, access to capital continues to underpin innovation throughout the sector.
The funding environment has become considerably more selective. Investors demand clearer value propositions, stronger governance, disciplined capital allocation and realistic development strategies.
Boards increasingly benefit from directors who understand:
- Public and private financing
- Investor relations
- Strategic partnerships
- Mergers and acquisitions
- IPO readiness
- Shareholder expectations
- Long-term value creation
Capital markets expertise is no longer simply about raising money.
It is about helping management allocate capital effectively while maintaining investor confidence through changing market conditions.
Beyond the Poll: What Else Will Boards Need?
While these four areas generated the strongest responses, I believe several additional capabilities will become increasingly important over the remainder of this decade.
Regulatory expertise remains invaluable as agencies adapt to new therapeutic modalities and digital technologies.
Cybersecurity and data privacy have become board-level risks requiring informed oversight.
Global market access and health economics are increasingly influencing investment decisions earlier in product development.
Patient-centricity is also reshaping how companies design clinical programmes and evaluate outcomes.
Perhaps most importantly, boards will need greater diversity—not only of gender and geography, but also of professional experience, cognitive approaches and industry backgrounds.
The most effective boards will combine scientific, commercial, financial, technological and operational perspectives to challenge management constructively and make better strategic decisions.
Looking Towards 2030
The biopharma industry is entering one of its most transformative periods.
Scientific breakthroughs continue to accelerate. Artificial intelligence is redefining discovery and development. Investors are becoming more selective. Patients expect faster access to innovative therapies, while regulators face increasingly complex technologies.
Against this backdrop, board composition is becoming a genuine source of competitive advantage.
Tomorrow’s strongest boards will not simply oversee governance.
They will help shape strategy, anticipate disruption, attract exceptional leadership, guide capital allocation and ensure organisations remain agile in an increasingly complex environment.
For nomination committees, the challenge is no longer finding experienced directors.
It is assembling boards whose collective capabilities reflect where the industry is heading—not where it has been.
The organisations that embrace this shift today are likely to be the ones creating the greatest value by 2030.
I’d be interested to hear your perspective.
Which board capability do you believe will become the biggest differentiator over the next five years? Are there competencies you believe are missing from this discussion?
